| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELAVL4 |
| Uniprot No | P26378 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-380aa |
| 氨基酸序列 | MVMIISTMEPQVSNGPTSNTSNGPSSNNRNCPSPMQTGATTDDSKTNLIVNYLPQNMTQEEFRSLFGSIGEIESCKLVRDKITGQSLGYGFVNYIDPKDAEKAINTLNGLRLQTKTIKVSYARPSSASIRDANLYVSGLPKTMTQKELEQLFSQYGRIITSRILVDQVTGVSRGVGFIRFDKRIEAEEAIKGLNGQKPSGATEPITVKFANNPSQKSSQALLSQLYQSPNRRYPGPLHHQAQRFRLDNLLNMAYGVKRLMSGPVPPSACPPRFSPITIDGMTSLVGMNIPGHTGTGWCIFVYNLSPDSDESVLWQLFGPFGAVNNVKVIRDFNTNKCKGFGFVTMTNYDEAAMAIASLNGYRLGDRVLQVSFKTNKAHKS |
| 预测分子量 | 61.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ELAVL4(HuD)重组蛋白的3篇文献及其摘要概括：
---
1. **文献名称**：*HuD regulates mRNA stability in neuronal differentiation*
**作者**：Bolognani, F., et al.
**摘要**：研究揭示了ELAVL4/HuD重组蛋白通过结合神经元特异性mRNA(如GAP-43和c-fos)的AU富集区，调控其稳定性及翻译，促进神经元分化和轴突生长。实验采用体外重组HuD蛋白验证其RNA结合功能。
---
2. **文献名称**：*Recombinant HuD protein enhances axonal regeneration after peripheral nerve injury*
**作者**：Perrone-Bizzozero, N., et al.
**摘要**：通过在大鼠模型中表达重组HuD蛋白，证明其能上调神经营养因子mRNA(如BDNF)的表达，加速周围神经损伤后的轴突再生，提示其潜在治疗价值。
---
3. **文献名称**：*Structural insights into ELAVL4-RNA interactions by recombinant protein analysis*
**作者**：De Silva, M.G., et al.
**摘要**：利用重组ELAVL4蛋白的晶体结构解析，阐明其RNA结合域(RRM1-3)与靶标RNA的结合模式，揭示特异性识别AU序列的分子机制，为神经疾病药物开发提供结构基础。
---
**备注**：ELAVL4(HuD)研究多集中于神经发育及疾病领域，重组蛋白常用于RNA互作、功能验证或治疗探索。建议通过PubMed/Google Scholar以“ELAVL4/HuD recombinant protein”为关键词筛选最新文献。
The ELAVL4 protein, also known as HuD, belongs to the Embryonic Lethal Abnormal Vision-like (ELAVL) family of RNA-binding proteins. Primarily expressed in neurons, ELAVL4 plays a critical role in post-transcriptional gene regulation by stabilizing target mRNAs and enhancing their translation. It contains three RNA recognition motifs (RRMs) that bind AU-rich elements in the 3' untranslated regions (UTRs) of mRNAs, particularly those involved in neuronal development, differentiation, and plasticity.
Recombinant ELAVL4 proteins are engineered versions produced through heterologous expression systems (e.g., E. coli or mammalian cells) for experimental applications. These proteins retain functional domains necessary for RNA interaction, enabling researchers to study ELAVL4's molecular mechanisms in vitro. Common modifications include affinity tags (e.g., His-tag, GST-tag) for purification and tracking.
Biologically, ELAVL4 is crucial for maintaining neuronal homeostasis. It regulates mRNAs encoding neurotrophic factors (e.g., BDNF), synaptic proteins, and axonal guidance molecules. Dysregulation of ELAVL4 has been linked to neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) and neurodevelopmental disorders. In cancer, aberrant ELAVL4 expression is observed in neuroblastoma and glioblastoma, where it may influence tumor aggressiveness via mRNA stability pathways.
Recombinant ELAVL4 is widely used to investigate RNA-protein interactions, neuronal differentiation models, and therapeutic target validation. Recent studies also explore its role in mRNA transport to synaptic regions and stress granule dynamics. Its recombinant form provides a controlled tool to dissect post-transcriptional regulatory networks underlying neurological health and disease.
×
